[go: up one dir, main page]

AR049268A1 - Proceso que emplea cristalizacion controlada en la formacion de cristales de un producto farmaceutico. - Google Patents

Proceso que emplea cristalizacion controlada en la formacion de cristales de un producto farmaceutico.

Info

Publication number
AR049268A1
AR049268A1 ARP050101777A ARP050101777A AR049268A1 AR 049268 A1 AR049268 A1 AR 049268A1 AR P050101777 A ARP050101777 A AR P050101777A AR P050101777 A ARP050101777 A AR P050101777A AR 049268 A1 AR049268 A1 AR 049268A1
Authority
AR
Argentina
Prior art keywords
crystals
crystallization
pharmaceutical product
reagent
formation
Prior art date
Application number
ARP050101777A
Other languages
English (en)
Inventor
Soojin Kim
Chenkou Wei
Mark Lindrud
Hyei-Jha Chung
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049268(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR049268A1 publication Critical patent/AR049268A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)

Abstract

El proceso que emplea cristalizacion controlada en la formacion de cristales de un producto farmacéutico, que también son proporcionados los cristales de la sustancia farmacéutica producidos mediante el proceso anterior. Reivindicacion 1: Un proceso para la formacion de cristales de una sal de un producto farmacéutico por medio de una cristalizacion reactiva controlada caracterizado el proceso porque comprende: hacer reaccionar un primer reactivo con incrementos de un segundo reactivo agregado a una velocidad cada vez mayor de acuerdo a la ecuacion de formula (1), donde: V = Volumen del segundo reactivo agregado durante el período de tiempo t transcurrido; Vtotal = Volumen total del segundo reactivo para la conversion de la reaccion al 100%; t = Tiempo transcurrido en la cristalizacion; tTotal = Tiempo de cristalizacion total o el tiempo para la carga del segundo reactivo, para controlar el grado de reaccion y cinética de cristalizacion, y para formar cristales del producto farmacéutico resultante.
ARP050101777A 2004-05-04 2005-05-03 Proceso que emplea cristalizacion controlada en la formacion de cristales de un producto farmaceutico. AR049268A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56804304P 2004-05-04 2004-05-04
US60753304P 2004-09-07 2004-09-07

Publications (1)

Publication Number Publication Date
AR049268A1 true AR049268A1 (es) 2006-07-12

Family

ID=35320785

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050101776A AR048937A1 (es) 2004-05-04 2005-05-03 Proceso para preparar bisulfato de atazanavir forma e3 y material de configuracion c
ARP050101777A AR049268A1 (es) 2004-05-04 2005-05-03 Proceso que emplea cristalizacion controlada en la formacion de cristales de un producto farmaceutico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050101776A AR048937A1 (es) 2004-05-04 2005-05-03 Proceso para preparar bisulfato de atazanavir forma e3 y material de configuracion c

Country Status (8)

Country Link
US (1) US20050256314A1 (es)
EP (1) EP1758664A4 (es)
AR (2) AR048937A1 (es)
CL (1) CL2011003144A1 (es)
PE (2) PE20060466A1 (es)
RU (1) RU2385325C2 (es)
TW (3) TWI445697B (es)
WO (1) WO2005108380A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
US20100204470A1 (en) * 2006-06-27 2010-08-12 Sandoz Ag method for salt preparation
WO2009002829A2 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
ATE499927T1 (de) * 2007-06-22 2011-03-15 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
ES2359770T3 (es) * 2007-06-22 2011-05-26 Bristol-Myers Squibb Company Composiciones en comprimidos que contienen atazanavir.
CA2693620C (en) * 2007-07-10 2017-10-17 Boehringer Ingelheim International Gmbh Optical filling control of pharmaceutical capsules in capsule filling machines
WO2009014676A1 (en) * 2007-07-23 2009-01-29 Merck & Co., Inc. Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
EP2272830A1 (en) 2009-06-18 2011-01-12 Esteve Química, S.A. Preparation process of an antivirally heterocyclic azahexane derivative
CN104163787A (zh) * 2014-08-08 2014-11-26 山东威智医药工业有限公司 阿扎那韦及其硫酸盐的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940998A (en) * 1953-10-15 1960-06-14 Ajinomoto Kk Process for resolution of racemic glutamic acid and salts thereof
US4022776A (en) * 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5428048A (en) * 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
AU765128B2 (en) * 1999-03-22 2003-09-11 Bristol-Myers Squibb Company Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6254888B1 (en) * 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
YU34501A (sh) * 2000-05-26 2003-10-31 Pfizer Products Inc. Postupak reaktivne kristalizacije radi povećanja veličine čestica
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法

Also Published As

Publication number Publication date
TW200606142A (en) 2006-02-16
PE20060466A1 (es) 2006-06-01
CL2011003144A1 (es) 2012-04-13
RU2385325C2 (ru) 2010-03-27
AR048937A1 (es) 2006-06-14
EP1758664A4 (en) 2010-12-22
TWI445697B (zh) 2014-07-21
WO2005108380A2 (en) 2005-11-17
TWI518072B (zh) 2016-01-21
PE20060216A1 (es) 2006-03-17
EP1758664A2 (en) 2007-03-07
WO2005108380A3 (en) 2006-08-24
US20050256314A1 (en) 2005-11-17
TW200600498A (en) 2006-01-01
RU2006142768A (ru) 2008-06-10
TW201427949A (zh) 2014-07-16

Similar Documents

Publication Publication Date Title
AR049268A1 (es) Proceso que emplea cristalizacion controlada en la formacion de cristales de un producto farmaceutico.
MX339033B (es) Derivados de acido antranilico.
AR074811A1 (es) Profarmaco de peptido de la superfamilia de glucagon basados en amida
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
PE20110288A1 (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
GEP20115359B (en) Fused cyclic compounds
SA518400696B1 (ar) معدِّلات صغيرة الجزيء لإنزيمات بانتوثينات كيناز
CY1118637T1 (el) Νεα κρυσταλλικη μορφη iii της αγομελατινης, μεθοδος παρασκευης αυτης και οι φαρμακευτικες συνθεσεις που την περιεχουν
ATE488184T1 (de) Vorrichtung zur endoskopischen magenbegrenzung
PE20081311A1 (es) Metodos que usan 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona para el tratamiento de linfomas de las celulas del manto
PE20090484A1 (es) Moduladores de calicreina 7
CY1111701T1 (el) Υδροχλωρικο αλας του 5-[3-(3-υδροξυφαινοξυ)αζετιδιν-1-υλ]-5-μεθυλ-2,2-διφαινυλεξαναμιδιου
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
EP2207439A4 (en) PORTABLE BELT FOR RECEIVING MEDICAL HOSES AND CABLES
AR053012A1 (es) Polimorfo a de ibandronato
AR083166A1 (es) Derivados de alquil-piperazin-fenil 4(3h)-quinazolinonas utiles para tratar depresion, ansiedad, disfunciones sexuales femeninas y otras patologias del sistema nervioso central, y composiciones farmaceuticas que los contienen
ATE450262T1 (de) Harnstoff-derivate als calcium-rezeptor- modulatoren
RU2012106467A (ru) Соединения для лечения воспаления
Gadakh et al. N-Acylated sulfonamide congeners of fosmidomycin lack any inhibitory activity against DXR
CN109110064A (zh) 一种水产养殖消毒用远程操控投放船
ES2536785T3 (es) Procedimiento para enriquecer cultivos con yodo, y cultivos obtenidos de este modo
ES2267421T1 (es) Procedimiento para la preparacion de acido (6rs)-n(5)-formil-5,6,7,8-tetrahidrofolico cristalino.
ES2720366T3 (es) Compuesto de pirazol y uso farmacéutico del mismo
CN104059106B (zh) 一种磷酸糖醇类四氢噻唑‑4‑羧酸化合物的制备方法

Legal Events

Date Code Title Description
FA Abandonment or withdrawal